256 related articles for article (PubMed ID: 25004955)
1. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
2. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.
Alain T; Morita M; Fonseca BD; Yanagiya A; Siddiqui N; Bhat M; Zammit D; Marcus V; Metrakos P; Voyer LA; Gandin V; Liu Y; Topisirovic I; Sonenberg N
Cancer Res; 2012 Dec; 72(24):6468-76. PubMed ID: 23100465
[TBL] [Abstract][Full Text] [Related]
3. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ; Borden KL
Immunol Rev; 2015 Jan; 263(1):210-23. PubMed ID: 25510279
[TBL] [Abstract][Full Text] [Related]
4. Translation initiation: a critical signalling node in cancer.
Robert F; Pelletier J
Expert Opin Ther Targets; 2009 Nov; 13(11):1279-93. PubMed ID: 19705976
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Liang S; Guo R; Zhang Z; Liu D; Xu H; Xu Z; Wang X; Yang L
Oncol Rep; 2013 Jun; 29(6):2422-30. PubMed ID: 23588929
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
7. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.
Martínez A; Sesé M; Losa JH; Robichaud N; Sonenberg N; Aasen T; Ramón Y Cajal S
PLoS One; 2015; 10(4):e0123352. PubMed ID: 25923732
[TBL] [Abstract][Full Text] [Related]
10. Meal feeding enhances formation of eIF4F in skeletal muscle: role of increased eIF4E availability and eIF4G phosphorylation.
Vary TC; Lynch CJ
Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E631-42. PubMed ID: 16263769
[TBL] [Abstract][Full Text] [Related]
11. Signalling to eIF4E in cancer.
Siddiqui N; Sonenberg N
Biochem Soc Trans; 2015 Oct; 43(5):763-72. PubMed ID: 26517881
[TBL] [Abstract][Full Text] [Related]
12. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
13. Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.
Yan J; Zhou H; Kong L; Zhang J; Zhao Q; Li Y
Cancer Chemother Pharmacol; 2013 Oct; 72(4):799-808. PubMed ID: 23934262
[TBL] [Abstract][Full Text] [Related]
14. Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
Graff JR; Konicek BW; Carter JH; Marcusson EG
Cancer Res; 2008 Feb; 68(3):631-4. PubMed ID: 18245460
[TBL] [Abstract][Full Text] [Related]
15. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.
Hsieh AC; Ruggero D
Clin Cancer Res; 2010 Oct; 16(20):4914-20. PubMed ID: 20702611
[TBL] [Abstract][Full Text] [Related]
16. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
17. Targeting translation: eIF4E as an emerging anticancer drug target.
Lu C; Makala L; Wu D; Cai Y
Expert Rev Mol Med; 2016 Jan; 18():e2. PubMed ID: 26775675
[TBL] [Abstract][Full Text] [Related]
18. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
Jin X; Jin HR; Lee D; Lee JH; Kim SK; Lee JJ
Eur J Pharmacol; 2008 Sep; 592(1-3):41-7. PubMed ID: 18639543
[TBL] [Abstract][Full Text] [Related]
19. A blood pact: the significance and implications of eIF4E on lymphocytic leukemia.
Venturi V; Masek T; Pospisek M
Physiol Res; 2018 Jul; 67(3):363-382. PubMed ID: 29527921
[TBL] [Abstract][Full Text] [Related]
20. Eukaryotic initiation factor 4E (eIF4E): A recap of the cap-binding protein.
Batool A; Aashaq S; Andrabi KI
J Cell Biochem; 2019 Sep; 120(9):14201-14212. PubMed ID: 31074051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
